The fiber metabolite butyrate reduces gp130 by targeting TRAF5 in colorectal cancer cells.

Cancer Cell Int

State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003 China.

Published: June 2020

Background: Dietary fiber is effective for colorectal cancer (CRC) treatment. Interleukin-6 (IL-6) and its adaptors are potential targets for CRC therapy. Butyrate, a metabolite of dietary fiber, is a new, highly safe type of targeted drug.

Methods: In this study, Cell Counting Kit-8 cell viability and wound healing assays, western blot analysis, immunofluorescence staining, and xenograft tumor mouse models were used to evaluate the anticancer effect of butyrate and its possible mechanism in vivo and in vitro.

Results: Dietary fiber and sodium butyrate (NaB) decreased CRC burden by decreasing IL-6 receptor gp130 and blocking IL-6/JAK2/STAT3 axis activation in vitro and in vivo. Furthermore, NaB reduced the gp130 protein level by regulating its degradation rate via targeting TRAF5.

Conclusions: The fiber metabolite butyrate inhibits CRC development by reducing gp130 via TRAF5.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271451PMC
http://dx.doi.org/10.1186/s12935-020-01305-9DOI Listing

Publication Analysis

Top Keywords

dietary fiber
12
fiber metabolite
8
metabolite butyrate
8
colorectal cancer
8
fiber
5
butyrate
5
butyrate reduces
4
gp130
4
reduces gp130
4
gp130 targeting
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!